William Blair & Company represented AmniSure International, LLC in connection with its sale to Qiagen NV.
Headquartered in Boston, MA, with subsidiaries in France, Germany, Spain and Russia, AmniSure was founded in 2005 to manufacture, market, and distribute the AmniSure® ROM Test, a diagnostic test for ruptured fetal membranes (ROM). Accurately testing for ROM is a long-standing problem in obstetric care. Competing methods date from the last century and have inferior accuracy while also being invasive and labor-intensive. AmniSure® ROM delivers unambiguous, rapid and accurate ROM diagnosis, positioning it as the leading technology and the gold standard test.
QIAGEN N.V., a Netherlands holding company, is the leading global provider of Sample & Assay Technologies that are used to transform biological materials into valuable molecular information. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are then used to make these isolated biomolecules visible and ready for interpretation. QIAGEN markets more than 500 products around the world, selling both consumable kits and automation systems to customers through four customer classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research).
AmniSure International engaged William Blair to assist it in pursuing a sale of the Company. In conjunction with the engagement, William Blair created a management presentation, marketed the Company to strategic acquirers, coordinated the due diligence process, drove a highly competitive process and assisted in the negotiation of the definitive purchase agreement.
For additional information about how the investment banking professionals at William Blair can help your business or portfolio company, please visit our website, williamblair.com, or contact us via e-mail at firstname.lastname@example.org.